M&A
![Bristol Myers Squibb acquires Mirati Therapeutics in a $5.8 billion deal to expand its cancer treatment portfolio](https://pharmtales.com/wp-content/uploads/2023/10/BMS-buys-Mirati-for-5.8B-to-boost-cancer-drugs.jpg)
Bristol Myers Squibb acquires Mirati Therapeutics in a $5.8 billion deal to expand its cancer treatment portfolio
Mirati Therapeutics, long speculated to be a potential acquisition target in the world of Big Pharma, has now sealed a ...
![Amgen Successfully Completes $27.8B Acquisition of Horizon After FTC Dispute Resolution](https://pharmtales.com/wp-content/uploads/2023/10/Amgen-Successfully-Completes-27.8B-Acquisition-of-Horizon-After-FTC-Dispute-Resolution.jpg)
Amgen Successfully Completes $27.8B Acquisition of Horizon After FTC Dispute Resolution
Amgen has successfully concluded its monumental $27.8 billion acquisition of Horizon Therapeutics, triumphing over a legal challenge posed by the ...
![Sanofi Considers Acquisition of Mirati Amid Intensifying KRAS Cancer Drug Battle, Reports Bloomberg](https://pharmtales.com/wp-content/uploads/2023/10/Sanofi-Considers-Acquisition-of-Mirati-Amid-Intensifying-KRAS-Cancer-Drug-Battle-Reports-Bloomberg.jpg)
Sanofi Considers Acquisition of Mirati Amid Intensifying KRAS Cancer Drug Battle, Reports Bloomberg
Mirati Therapeutics experienced a significant surge in its stock price on Thursday, triggered by swirling rumors of a potential acquisition ...
![AbbVie acquires mitochondria biotech to boost Parkinson’s research](https://pharmtales.com/wp-content/uploads/2023/10/AbbVie-acquires-mitochondria-biotech-to-boost-Parkinsons-research.jpg)
AbbVie acquires mitochondria biotech to boost Parkinson’s research
AbbVie has made a significant move in the field of Parkinson’s disease by acquiring Mitokinin for an upfront payment of ...
![Lilly Makes a Splash in Radiopharmaceuticals with $1.4B Acquisition of Point Biopharma](https://pharmtales.com/wp-content/uploads/2023/10/Lilly-Makes-a-Splash-in-Radiopharmaceuticals-with-1.4B-Acquisition-of-Point-Biopharma.jpg)
Lilly Makes a Splash in Radiopharmaceuticals with $1.4B Acquisition of Point Biopharma
Eli Lilly is making a significant foray into the radiopharmaceutical cancer therapeutic sector with its acquisition of Point Biopharma Global ...
![Intercept Pharmaceuticals, After 2 FDA Setbacks and Restructuring Efforts, Finds a Buyer in Italy's Alfasigma](https://pharmtales.com/wp-content/uploads/2023/09/Intercept-agrees-to-be-acquired-by-Alfasigma-for-800-million-after-failed-NASH-bids.jpg)
Intercept Pharmaceuticals, After 2 FDA Setbacks and Restructuring Efforts, Finds a Buyer in Italy’s Alfasigma
Intercept Pharmaceuticals has faced substantial challenges over the past three years, particularly after the FDA rejected its attempts to bring ...
![Contract research organization, mergers and acquisitions, diagnostics, clinical trial supplies, M&A, Cerba HealthCare, Cirion Biopharma](https://pharmtales.com/wp-content/uploads/2023/09/Cerba-HealthCare-buys-Cirion-Biopharma-to-boost-bioanalytical-services.jpg)
Cerba HealthCare buys Cirion Biopharma to boost bioanalytical services
French clinical trial lab and diagnostics provider Cerba HealthCare has acquired Canadian CRO Cirion Biopharma in a move aimed at ...
![Calidi Biotherapeutics, SPAC, cell therapy, allogeneic, off-the-shelf treatment, Special purpose acquisition company, M&A](https://pharmtales.com/wp-content/uploads/2023/09/Calidi-Biotherapeutics-goes-public-through-SPAC-deal-to-advance-off-the-shelf-cancer-treatments.jpg)
Calidi Biotherapeutics goes public through SPAC deal to advance off-the-shelf cancer treatments
Calidi Biotherapeutics, a San Diego-based biotech, has chosen the special purpose acquisition company (SPAC) path to enter the public market, ...
![Kriya Therapeutics, NASH, Cell & Gene Therapy, M&A, nonalcoholic steatohepatitis](https://pharmtales.com/wp-content/uploads/2023/09/Kriya-acquires-gene-therapy-biotech-to-enter-NASH-market-with-novel-approach.jpg)
Kriya Acquires Gene Therapy Biotech To Enter NASH Market With Novel Approach
Kriya Therapeutics, a prominent player in the biotech industry, has continued its acquisition spree, this time securing Tramontane Therapeutics to ...
![M&A, Stallergenes Greer, Palforzia, Nestlé, Peanut allergy, agreements](https://pharmtales.com/wp-content/uploads/2023/09/Nestle-sells-Aimmune-and-its-peanut-allergy-drug-Palforzia-to-Parvus-Therapeutics.jpg)
Nestlé abandons $2 billion peanut allergy drug Palforzia after disappointing sales and safety issues
Nestlé has completed the sale of its peanut allergy drug, Palforzia, to the U.S.-based allergy specialist Stallergenes Greer for an ...
![Otsuka, psychedelics, Mindset Pharma, M&A, Acquisition, MSP-1014](https://pharmtales.com/wp-content/uploads/2023/09/Otsuka-acquires-Mindset-Pharma-a-leader-in-psychedelic-medicines-for-mental-health.jpg)
Otsuka acquires Mindset Pharma, a leader in psychedelic medicines for mental health
Japanese pharmaceutical giant Otsuka is embarking on a groundbreaking acquisition, setting its sights on Canada’s Mindset Pharma, a specialist in ...
![Amgen, Horizon Therapeutics, US Federal Trade Commission, M&A](https://pharmtales.com/wp-content/uploads/2023/09/Amgen-seals-the-deal-with-Horizon-for-28-billion-expanding-its-portfolio-of-rare-disease-drugs.jpg)
Amgen seals the deal with Horizon for $28 billion, expanding its portfolio of rare disease drugs
After several months of legal battles, Amgen has finally received the green light for its $27.8 billion acquisition of Horizon ...
![Serina Therapeutics, M&A, AgeX Therapeutics, Parkinson disease,](https://pharmtales.com/wp-content/uploads/2023/08/Serina-Therapeutics-merges-with-struggling-AgeX-Therapeutics-to-go-public-and-advance-its-Parkinsons-drug.jpg)
Serina Therapeutics merges with struggling AgeX Therapeutics to go public and advance its Parkinson’s drug
AgeX Therapeutics, a biotech that has been facing financial difficulties and stalled preclinical programs for years, has finally found a ...
![Danaher, Abcam, Antibody Portfolio, Acquisition, M&A, Danaher Buys Abcam](https://pharmtales.com/wp-content/uploads/2023/08/Abcams-Harmonious-Acquisition-by-Danaher-Shaping-the-Future-of-Antibody-Research.jpg)
Abcam’s Harmonious Acquisition by Danaher Shaping the Future of Antibody Research
In the realm where science meets commerce, a symphony of strategy and innovation is playing out. Just two months since ...
![Amgen, Horizon Therapeutics, Federal Trade Commission, M&A](https://pharmtales.com/wp-content/uploads/2023/08/Amgen-challenges-FTCs-bid-to-block-28B-Horizon-deal.jpg)
Amgen challenges FTC’s bid to block $28B Horizon deal
Amid the ongoing legal battle with the Federal Trade Commission (FTC) over its $28 billion acquisition of Horizon Therapeutics, Amgen ...
![LEO Pharma, M&A, Timber Pharmaceuticals, Acquisition](https://pharmtales.com/wp-content/uploads/2023/08/LEO-Pharma-Set-to-Acquire-Timber-Pharmaceuticals.jpg)
LEO Pharma Set to Acquire Timber Pharmaceuticals
Timber Pharmaceuticals has exciting news to share—the company is set to be acquired by LEO US Holding, Inc., a wholly-owned ...
![Biogen, Reata Pharmaceuticals, M&A, acquisition,](https://pharmtales.com/wp-content/uploads/2023/08/Biogen-Outbids-Competitor-in-7.3-Billion-Reata-Pharmaceuticals-Acquisition-Duel.jpg)
Biogen Outbids Competitor in $7.3 Billion Reata Pharmaceuticals Acquisition Duel
In a surprising turn of events, Biogen’s acquisition of Reata Pharmaceuticals for $7.3 billion raised eyebrows among industry observers last ...
![Novartis Buys Chinook Therapeutics for $1.7 Billion](https://pharmtales.com/wp-content/uploads/2023/08/Novartis-Acquires-Chinook-Therapeutics-for-USD-3.5-Billion-to-Boost-its-Renal-Portfolio.jpg)
Novartis Acquires Chinook Therapeutics for USD 3.5 Billion to Boost its Renal Portfolio
Novartis, a global pharmaceutical giant, has finalized its deal to buy Chinook Therapeutics, a biotech company that specializes in developing ...
![Babylon, M&A, Digital health, US Operations, Failed Merger](https://pharmtales.com/wp-content/uploads/2023/08/Babylon-shutters-its-US-operations-after-a-failed-rescue-merger-deal.jpg)
Babylon shutters its US operations after a failed rescue merger deal
Babylon Health’s efforts to secure funding and stabilize its operations have been thwarted due to the collapse of a planned ...
![eureKING, SCTbio, M&A, Contract manufacturing](https://pharmtales.com/wp-content/uploads/2023/08/eureKING-purchases-SCTbio-to-further-its-bio-manufacturing-initiative.jpg)
eureKING purchases SCTbio to further its bio manufacturing initiative
eureKING, a special purpose acquisition company (SPAC) established last year with a substantial investment of over €150 million, has finalized ...
![How PacBio’s Acquisition of Apton Biosystems Will Transform Sequencing](https://pharmtales.com/wp-content/uploads/2023/08/PacBio-to-Acquire-Apton-Biosystems-for-Next-Gen-Short-Read-Sequencer-Development.jpg)
PacBio to Acquire Apton Biosystems for Next-Gen Short-Read Sequencer Development
Source – PacBio Gene sequencing specialist PacBio has signed an agreement to acquire Apton Biosystems, a move that will enhance ...
![EQRx Buys Revolution Medicines for $2.3B in Low-Cost Drugs Quest](https://pharmtales.com/wp-content/uploads/2023/08/How-EQRxs-Cheap-Drugs-Strategy-Led-to-Revolution-Deal.jpg)
How EQRx’s Cheap Drugs Strategy Led to Revolution Deal
Source – Revolution Medicines EQRx, which made a bold claim to disrupt the pharmaceutical pricing system in 2020, has now ...
![Merck’s M&A Strategy: Why Prometheus Is Not Enough](https://pharmtales.com/wp-content/uploads/2023/08/Even-after-buying-Prometheus-for-10.8-billion-Merck-is-still-looking-for-MA-opportunities.jpg)
Even after buying Prometheus for $10.8 billion, Merck is still looking for M&A opportunities
Earlier this year, Merck’s acquisition of Prometheus Biosciences for $10.8 billion provided the New Jersey company with a much-needed diversification ...
![Biogen Acquires Reata Pharmaceuticals and Skyclarys for $7.3B Amid Layoffs](https://pharmtales.com/wp-content/uploads/2023/07/Biogen-Buys-Reata-and-Skyclarys-for-7.3B-Cuts-Jobs.jpg)
Biogen Buys Reata and Skyclarys for $7.3B, Cuts Jobs
During a quarterly earnings call, Biogen CEO Chris Viehbacher unexpectedly mentioned that the company had around $7.3 billion in cash. ...
![Sosei Buys Idorsia’s Japan and Korea Units for $466 Million](https://pharmtales.com/wp-content/uploads/2023/07/In-a-466-million-agreement-Sosei-acquires-the-Japan-and-Korea-subsidiaries-of-Idorsia.jpg)
In a $466 million agreement, Sosei acquires the Japan and Korea subsidiaries of Idorsia
Source – Sosei Heptares Japan’s Sosei Group has successfully transformed into a commercial-stage pharmaceutical company by acquiring the rights to ...
![FTC and DOJ to Scrutinize M&A Deals More Closely Under New Guidelines](https://pharmtales.com/wp-content/uploads/2023/07/Enhanced-Merger-Standards-by-FTC-and-DOJ-Signal-Heightened-Scrutiny-of-MA-Transactions.jpg)
Enhanced Merger Standards by FTC and DOJ Signal Heightened Scrutiny of M&A Transactions
As the Federal Trade Commission (FTC) closely examines two significant biopharma mergers, both the FTC and the Department of Justice ...
![Healthcare bucks the trend with a 2-year M&A high](https://pharmtales.com/wp-content/uploads/2023/07/Healthcare-bucks-the-trend-with-a-2-year-MA-high.jpg)
Healthcare bucks the trend with a 2-year M&A high
On July 4, Data from LSEG Deals Intelligence revealed that the healthcare sector experienced a notable 35% increase in deals, ...